Hormone-refractory prostate cancer: a multi-step and multi-event process (Q35032556)

5 August 2017

Hormone-refractory prostate cancer: a multi-step and multi-event process (English)

1 reference

5 August 2017

1 reference

A De La Taille

1

1 reference

5 August 2017

F Vacherot

2

1 reference

5 August 2017

L Salomon

3

1 reference

5 August 2017

C Druel

4

1 reference

5 August 2017

S Gil Diez De Medina

5

1 reference

5 August 2017

C Abbou

6

1 reference

5 August 2017

R Buttyan

7

1 reference

5 August 2017

D Chopin

8

1 reference

5 August 2017

1 January 2001

1 reference

Prostate Cancer and Prostatic Diseases

5 August 2017

1 reference

5 August 2017

4

1 reference

5 August 2017

4

1 reference

5 August 2017

204-212

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.pcan.4500534

5 August 2017

0 references

cites work

Cancer statistics, 1994.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Studies on Prostatic Cancer: I. The Effect of Castration, Of Estrogen and of Androgen Injection on Serum Phosphatases in Metastatic Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The biology of hormone refractory prostate cancer. Why does it develop?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Androgen receptors in endocrine-therapy-resistant human prostate cancer.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostatic carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Resistance to apoptosis and up regulation of Bcl-2 in benign prostatic hyperplasia after androgen deprivation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Abnormal prostate development in C3(1)-bcl-2 transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Bcl-2 accelerates multistep prostate carcinogenesis in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Castration plus oestrogen treatment induces but castration alone suppresses epithelial cell apoptosis in an androgen-sensitive rat prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The p53 tumour suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p21--negative regulator of the cell cycle

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Mutations in the p53 gene occur in diverse human tumour types

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The role of the p53 tumor suppressor gene in prostate cancer: a possible biomarker?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Clinical implications of the p53 tumor-suppressor gene

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p53 expression and clinical outcome in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p53 function and dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p53 mutations in human cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

p73 is a simian [correction of human] p53-related protein that can induce apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Androgen receptors in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

In vivo amplification of the androgen receptor gene and progression of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Androgen-repressed phenotype in human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The role of APO-1-mediated apoptosis in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Portrait of an executioner: the molecular mechanism of FAS/APO-1-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Enhanced expression of the c-myc protooncogene in high-grade human prostate cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Molecular analysis of the INK4 family of genes in prostate carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

International comparison on ras gene mutations in latent prostate carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Allelic loss of chromosomes 16q and 10q in human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Neuroendocrine differentiation in human prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Neuroendocrine peptides in the prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

The Prognostic Value of Neuroendocrine Differentiation in Adenocarcinoma of the Prostate in Relation to Progression of Disease After Endocrine Therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Neuroendocrine cells in benign prostatic hyperplasia and prostatic carcinoma: effect of hormonal treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Neuroendocrine differentiation in prostate cancer: enhanced prediction of progression after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Investigation on serum neurone-specific enolase in prostate cancer diagnosis and monitoring: Comparative study of a multiple tumor marker assay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3'-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Fas gene mutations in prostatic intraepithelial neoplasia and concurrent carcinoma: analysis of laser capture microdissected specimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Cytometric analysis of Fas and Bcl-2 expression in normal prostatic epithelium and prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.PCAN.4500534

7 January 2021

Identifiers

DOI

10.1038/SJ.PCAN.4500534

1 reference

5 August 2017

1 reference